CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 48 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,400,000 | -30.4% | 622,548 | -14.7% | 0.38% | -22.3% |
| Q3 2018 | $13,504,000 | -19.1% | 729,948 | 0.0% | 0.48% | -17.4% |
| Q2 2018 | $16,687,000 | -22.1% | 729,948 | -3.1% | 0.59% | -21.1% |
| Q1 2018 | $21,432,000 | +34.8% | 753,322 | 0.0% | 0.74% | +18.7% |
| Q4 2017 | $15,903,000 | +15.6% | 753,322 | -0.5% | 0.63% | +1.1% |
| Q3 2017 | $13,751,000 | +17.2% | 756,822 | 0.0% | 0.62% | -1.1% |
| Q2 2017 | $11,731,000 | -28.0% | 756,822 | -19.8% | 0.63% | -0.3% |
| Q1 2017 | $16,293,000 | +57.1% | 943,433 | 0.0% | 0.63% | +47.1% |
| Q4 2016 | $10,368,000 | -29.9% | 943,433 | 0.0% | 0.43% | -37.9% |
| Q3 2016 | $14,793,000 | +53.5% | 943,433 | 0.0% | 0.69% | +81.5% |
| Q2 2016 | $9,637,000 | -20.8% | 943,433 | 0.0% | 0.38% | -26.8% |
| Q1 2016 | $12,170,000 | -38.4% | 943,433 | -0.3% | 0.52% | -35.2% |
| Q4 2015 | $19,743,000 | – | 946,022 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |